Published in Arch Ophthalmol on September 12, 2011
Color Vision as a Measure for Inherited Retinal Diseases | NCT01878032
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet (2014) 4.24
Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med (2015) 3.16
Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A (2013) 2.71
Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med (2015) 2.68
Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet (2014) 2.16
Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A (2012) 2.12
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood (2013) 2.09
NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet (2012) 1.86
Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology (2013) 1.85
A comprehensive review of retinal gene therapy. Mol Ther (2013) 1.70
X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res (2012) 1.66
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther (2013) 1.54
Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease. Invest Ophthalmol Vis Sci (2012) 1.47
Comprehensive molecular diagnosis of 179 Leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next generation sequencing. J Med Genet (2013) 1.47
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One (2013) 1.33
AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One (2012) 1.28
Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Invest Ophthalmol Vis Sci (2012) 1.26
Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice. Stem Cell Reports (2014) 1.22
The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum Gene Ther (2012) 1.16
Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. Mol Ther (2013) 1.10
Advances in gene therapy technologies to treat retinitis pigmentosa. Clin Ophthalmol (2013) 1.10
Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum Mol Genet (2012) 1.10
Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo. J Mol Med (Berl) (2013) 1.09
Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV Restores ON and OFF visual responses in blind mice. Mol Ther (2014) 1.08
Concise Review: Patient-Specific Stem Cells to Interrogate Inherited Eye Disease. Stem Cells Transl Med (2015) 1.08
Gene therapy for choroideremia using an adeno-associated viral (AAV) vector. Cold Spring Harb Perspect Med (2014) 1.06
Poly(β-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo. PLoS One (2012) 1.06
Human cone visual pigment deletions spare sufficient photoreceptors to warrant gene therapy. Hum Gene Ther (2013) 1.06
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum Gene Ther (2013) 1.03
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. Cell Rep (2015) 1.03
Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. J Clin Invest (2014) 1.01
Intravitreal delivery of AAV-NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy. Eur J Hum Genet (2012) 0.98
Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc Natl Acad Sci U S A (2015) 0.97
Chemical chaperone TUDCA preserves cone photoreceptors in a mouse model of Leber congenital amaurosis. Invest Ophthalmol Vis Sci (2012) 0.97
Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale. Exp Eye Res (2014) 0.97
RPGR: Its role in photoreceptor physiology, human disease, and future therapies. Exp Eye Res (2015) 0.97
Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene Ther (2013) 0.97
Gene therapy for Leber congenital amaurosis: advances and future directions. Graefes Arch Clin Exp Ophthalmol (2012) 0.95
Rescue of enzymatic function for disease-associated RPE65 proteins containing various missense mutations in non-active sites. J Biol Chem (2014) 0.95
Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res (2014) 0.94
Gene therapy: progress and predictions. Proc Biol Sci (2015) 0.94
Stem cells for investigation and treatment of inherited retinal disease. Hum Mol Genet (2014) 0.94
Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet (2016) 0.94
Halting progressive neurodegeneration in advanced retinitis pigmentosa. J Clin Invest (2015) 0.93
Müller glia activation in response to inherited retinal degeneration is highly varied and disease-specific. PLoS One (2015) 0.93
Cortical inhibition, pH and cell excitability in epilepsy: what are optimal targets for antiepileptic interventions? J Physiol (2012) 0.93
Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci (2014) 0.93
Clinical characteristics and current therapies for inherited retinal degenerations. Cold Spring Harb Perspect Med (2014) 0.92
Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther (2014) 0.92
Pseudo-fovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci (2014) 0.91
Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs. PLoS One (2013) 0.91
Automated retinofugal visual pathway reconstruction with multi-shell HARDI and FOD-based analysis. Neuroimage (2015) 0.90
Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration. Proc Natl Acad Sci U S A (2015) 0.90
Immunology of AAV-Mediated Gene Transfer in the Eye. Front Immunol (2013) 0.90
RPGR-associated retinal degeneration in human X-linked RP and a murine model. Invest Ophthalmol Vis Sci (2012) 0.90
Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients. Hum Gene Ther (2012) 0.90
[Gene therapy for retinal dystrophies]. Ophthalmologe (2012) 0.90
Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina. PLoS One (2013) 0.90
AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene replacement therapy rescues retinal degeneration in rd11 mice. Invest Ophthalmol Vis Sci (2014) 0.89
Subretinal injection of gene therapy vectors and stem cells in the perinatal mouse eye. J Vis Exp (2012) 0.89
Insights gained from gene therapy in animal models of retGC1 deficiency. Front Mol Neurosci (2014) 0.89
B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol Ther Methods Clin Dev (2014) 0.88
Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient. Mol Ther Methods Clin Dev (2014) 0.88
Center for fetal monkey gene transfer for heart, lung, and blood diseases: an NHLBI resource for the gene therapy community. Hum Gene Ther (2012) 0.88
Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium. Invest Ophthalmol Vis Sci (2015) 0.88
rAAV-mediated subcellular targeting of optogenetic tools in retinal ganglion cells in vivo. PLoS One (2013) 0.88
A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration. Hum Mol Genet (2015) 0.87
Gene therapy of inherited retinal degenerations: prospects and challenges. Hum Gene Ther (2015) 0.87
Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors. J Virol (2016) 0.85
The impact of cHS4 insulators on DNA transposon vector mobilization and silencing in retinal pigment epithelium cells. PLoS One (2012) 0.85
Review: the history and role of naturally occurring mouse models with Pde6b mutations. Mol Vis (2013) 0.85
New and emerging technologies for the treatment of inherited retinal diseases: a horizon scanning review. Eye (Lond) (2015) 0.85
A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials (2013) 0.85
Promising and delivering gene therapies for vision loss. Vision Res (2014) 0.85
Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev (2016) 0.85
Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases. Hum Gene Ther (2016) 0.84
Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindness. Hum Mol Genet (2015) 0.84
State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med (2014) 0.84
Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina. Hum Gene Ther (2016) 0.83
Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1. Gene Ther (2015) 0.83
Caspase inhibition with XIAP as an adjunct to AAV vector gene-replacement therapy: improving efficacy and prolonging the treatment window. PLoS One (2012) 0.83
Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin. Hum Gene Ther Clin Dev (2015) 0.83
Recombinant AAV-mediated BEST1 transfer to the retinal pigment epithelium: analysis of serotype-dependent retinal effects. PLoS One (2013) 0.83
Blue cone monochromacy: visual function and efficacy outcome measures for clinical trials. PLoS One (2015) 0.83
Persistence of non-viral vector mediated RPE65 expression: case for viability as a gene transfer therapy for RPE-based diseases. J Control Release (2013) 0.83
Prospectives for gene therapy of retinal degenerations. Curr Genomics (2012) 0.83
Towards a quantitative OCT image analysis. PLoS One (2014) 0.82
Gene replacement therapy for retinal CNG channelopathies. Mol Genet Genomics (2013) 0.82
Adeno-associated Virus as a Mammalian DNA Vector. Microbiol Spectr (2015) 0.82
Differential proteomics and functional research following gene therapy in a mouse model of Leber congenital amaurosis. PLoS One (2012) 0.82
Identification of a therapeutic dose of continuously delivered erythropoietin in the eye using an inducible promoter system. Curr Gene Ther (2013) 0.82
Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier. Ophthalmology (2016) 0.82
Capsid Mutated Adeno-Associated Virus Delivered to the Anterior Chamber Results in Efficient Transduction of Trabecular Meshwork in Mouse and Rat. PLoS One (2015) 0.82
CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight (2016) 0.81
Targeting sarcoplasmic reticulum calcium ATPase by gene therapy. Hum Gene Ther (2013) 0.81
The Rpe65 rd12 allele exerts a semidominant negative effect on vision in mice. Invest Ophthalmol Vis Sci (2014) 0.81
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev (2016) 0.80
Dog models for blinding inherited retinal dystrophies. Hum Gene Ther Clin Dev (2015) 0.80
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med (2008) 15.30
New visual acuity charts for clinical research. Am J Ophthalmol (1982) 12.72
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther (2008) 8.83
Gene therapy restores vision in a canine model of childhood blindness. Nat Genet (2001) 7.88
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A (2008) 7.16
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther (2005) 4.74
Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A (2005) 4.04
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol (2007) 3.86
Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology (1985) 3.83
Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A (2006) 3.49
Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol (1959) 3.32
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther (2009) 3.07
Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci (2004) 2.72
Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med (2009) 2.57
In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther (2004) 2.56
Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol Vis (2005) 2.55
The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci (2005) 2.40
Automated light- and dark-adapted perimetry for evaluating retinitis pigmentosa. Ophthalmology (1986) 2.34
Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther (2005) 2.27
Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci U S A (2007) 2.21
Cellular remodeling in mammalian retina: results from studies of experimental retinal detachment. Prog Retin Eye Res (2005) 2.21
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther (2006) 2.13
Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci (2008) 2.06
Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res (2005) 1.94
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res (2010) 1.81
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther (2006) 1.81
Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med (2007) 1.79
The cone-specific visual cycle. Prog Retin Eye Res (2010) 1.78
Association of visual field loss and mobility performance in older adults: Salisbury Eye Evaluation Study. Optom Vis Sci (2004) 1.69
Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med (2006) 1.67
Advantages and limitations of small gauge vitrectomy. Surv Ophthalmol (2011) 1.59
Identification of the RPE65 protein in mammalian cone photoreceptors. Invest Ophthalmol Vis Sci (2002) 1.57
Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci (2008) 1.54
RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-/- mice. Invest Ophthalmol Vis Sci (2006) 1.53
Laser flare-cell photometry: methodology and clinical applications. Surv Ophthalmol (2004) 1.50
Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65-/- knockout mouse eye results in limited rescue. Genet Vaccines Ther (2004) 1.47
Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci (2011) 1.46
Treatment possibilities for retinitis pigmentosa. N Engl J Med (2010) 1.40
Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther (2010) 1.33
Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas (2007) 1.31
Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. Mol Vis (2007) 1.26
Traditional measures of mobility performance and retinitis pigmentosa. Optom Vis Sci (1998) 1.25
Persistent subfoveal fluid and increased preoperative foveal thickness impair visual outcome after macula-off retinal detachment repair. Retina (2011) 1.18
Preliminary results of gene therapy for retinal degeneration. N Engl J Med (2008) 1.14
The relationship of primate foveal cones to the pigment epithelium. J Ultrastruct Res (1979) 1.10
Regeneration of photopigment is enhanced in mouse cone photoreceptors expressing RPE65 protein. J Neurosci (2011) 1.05
Improved mobility and independence of night-blind people using night-vision goggles. Invest Ophthalmol Vis Sci (2004) 0.99
Retinal disease in Rpe65-deficient mice: comparison to human leber congenital amaurosis due to RPE65 mutations. Invest Ophthalmol Vis Sci (2010) 0.95
Measuring mobility performance: experience gained in designing a mobility course. Clin Exp Optom (2006) 0.91
Comparison of functional mobility performance with clinical vision measures in simulated retinitis pigmentosa. Optom Vis Sci (1994) 0.90
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther (2008) 8.83
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol (2007) 8.12
Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation (2002) 7.97
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A (2008) 7.16
Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol (2004) 7.12
A muscleblind knockout model for myotonic dystrophy. Science (2003) 5.93
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 5.30
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther (2005) 4.74
Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol (2009) 4.21
Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11). Proc Natl Acad Sci U S A (2006) 4.16
Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A (2005) 4.04
Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol (2012) 3.93
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med (2002) 3.81
Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med (2010) 3.71
Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol (2009) 3.69
Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res (2006) 3.63
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A (2009) 3.58
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina (2006) 3.48
Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology (2012) 3.35
Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A (2003) 3.31
Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med (2015) 3.16
Bbs2-null mice have neurosensory deficits, a defect in social dominance, and retinopathy associated with mislocalization of rhodopsin. Proc Natl Acad Sci U S A (2004) 3.11
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther (2009) 3.07
Pompe disease diagnosis and management guideline. Genet Med (2006) 3.03
Bardet-Biedl syndrome type 4 (BBS4)-null mice implicate Bbs4 in flagella formation but not global cilia assembly. Proc Natl Acad Sci U S A (2004) 3.01
Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. Nat Genet (2002) 2.94
Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol (2006) 2.94
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther (2008) 2.93
Regulation of gene expression in the mammalian eye and its relevance to eye disease. Proc Natl Acad Sci U S A (2006) 2.91
Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology (2013) 2.83
Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol (2012) 2.82
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell (2012) 2.81
Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med (2006) 2.78
Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther (2011) 2.75
Reproducibility of peripapillary retinal nerve fiber thickness measurements with stratus OCT in glaucomatous eyes. Ophthalmology (2007) 2.75
Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. Am J Ophthalmol (2006) 2.73
Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci (2004) 2.72
Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A (2013) 2.71
Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. Ophthalmology (2010) 2.68
Comparative genomic analysis identifies an ADP-ribosylation factor-like gene as the cause of Bardet-Biedl syndrome (BBS3). Am J Hum Genet (2004) 2.67
Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med (2009) 2.57